Huimin Yuan

Huimin Yuan

Auto-generated profile, based on publicly available information

Huimin Yuan

Department of Pharmacology School of Pharmacy Tongji Medical College Huazhong University of Science and Technology Wuhan 430000 China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2025 in Medcomm
Verified
Journal Article
Open access
HYHuimin Yuan
Huimin Yuan
RXRuochen Xu
Ruochen Xu
SLSenlin Li
Senlin Li
MZMengzhu Zheng
Mengzhu Zheng
QTQingyi Tong
Qingyi Tong
YZYonghui Zhang
Yonghui Zhang
Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related mortality globally, predominantly associated with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. These infections drive persistent liver inflammation, culminating in cellular dysregulation, fibrosis, and cancer. Despite advancements in targeted therapies, drug resistance and the lack of reliable biomarkers for patient stratification still terribly hinder the treatment of viral HCC. To this end, the review delves into the intricate mechanisms underlying the malignant transformation of viral hepatitis to HCC, including viral integration, genomic instability, epigenetic modifications, oxidative stress, gut microbiota dysbiosis, chronic inflammation, immune escape, and abnormal signaling pathways, highlighting their complex interactions and synergies. Cutting‐edge preclinical and clinical advancements in HCC management, including lifestyle modifications, drug therapies, immunotherapies, gene‐based approaches, and innovative treatments, are further investigated, with particular priority given to their therapeutic potential and future applications in overcoming current limitations. By synthesizing recent scientific and clinical insights, this review aims to deepen the understanding of HCC pathogenesis in the context of chronic viral hepatitis, paving the way for novel therapeutic targets and personalized treatment strategies, ultimately improving patient outcomes.

14 June 2025 in Cellular & Molecular Biology Letters
Verified
Journal Article
Open access
PDF file
HYHuimin Yuan
Huimin Yuan
JLJia Liu
Jia Liu
RXRuochen Xu
Ruochen Xu
KYKeshan Yang
Keshan Yang
RQRuiyang Qu
Ruiyang Qu
MXMing Xiang
Ming Xiang
During the transformation of viral hepatitis into hepatocellular carcinoma (HCC), oxidative stress levels increase significantly, leading to tissue damage and chronic inflammation. HCC is characterized by spatiotemporal heterogeneity, which influences oxidative stress patterns, with reactive oxygen species (ROS) as the primary representative molecules. ROS serve not only as critical biomarkers of cancer but also as potential therapeutic targets for HCC, given that their increased levels can either promote or inhibit disease progression. In this review, we systematically examine the temporal heterogeneity of ROS, emphasizing its role in different stages of HCC progression caused by viral hepatitis and in influencing cell fate. We further explore ROS spatial heterogeneity at three levels: cellular, organelle, and biomolecular. Next, we comprehensively review clinical applications and potential therapies designed to selectively modulate ROS on the basis of its spatiotemporal heterogeneity. Finally, we discuss potential future applications of novel therapies that target ROS spatiotemporal heterogeneity to prevent and manage HCC onset and progression. In conclusion, this review enhances understanding of ROS in the progression of viral hepatitis to HCC and offers insights into developing new therapeutic targets and strategies centered on ROS heterogeneity.

16 November 2025 in Advanced Science
Verified
Journal Article
Open access
HYHuimin Yuan
Huimin Yuan
SLSenlin Li
Senlin Li
SLShuai Liu
Shuai Liu
HZHong Zhou
Hong Zhou
YXYue Xu
Yue Xu
MXMing Xiang
Ming Xiang
Type 1 diabetes (T1D) is an autoimmune disorder marked by the injury of pancreatic β cells, during which sympathetic neurons in the endocrine region of pancreas are lost, whereas those in the exocrine regions surrounding islets remain intact. This abnormal sympathetic nervous signaling may disrupt the balance of the neuroendocrine‐immune network and contribute to the development of T1D, although its underlying molecular mechanisms are still elusive. Here, single‐cell omics and whole‐tissue immunostaining reveal a decrease in pancreatic sympathetic nerve density in T1D patients and T1D mouse models. Surgical and chemical desensitization of the sympathetic nervous system exacerbates T1D, while macrophage depletion mitigates this effect. Mechanistically, diminished norepinephrine (NE) release impairs β2‐adrenergic receptor (β2‐AR)‐PKA‐CREB1 signaling in islet macrophages, leading to downregulation of the adaptor caspase recruitment domain family member 9 (CARD9). Loss of CARD9 decreases SLC6A8‐mediated creatine uptake, shifts macrophages toward a pro‐inflammatory phenotype, and promotes sympathetic axon ferroptosis driven by decreased neurotrophic factor and anti‐inflammatory factor release. Conversely, β2‐AR agonist formoterol restores PKA‐CREB1‐CARD9 activation, preserves creatine metabolism, and maintains anti‐inflammatory macrophage polarization. These findings define a novel sympathetic‐macrophage‐creatine metabolic axis governed by CARD9 that links neural signals to immune and metabolic regulation in T1D, highlighting neuroimmune interactions as targets for therapies.

15 June 2023 in Journal of Food Biochemistry
Verified
Journal Article
Open access
PDF file
KMKun Ma
Kun Ma
JHJialuo He
Jialuo He
HYHuimin Yuan
Huimin Yuan
JHJiayu He
Jiayu He
MXMing Xiang
Ming Xiang
Osteoporosis (OP) has been a global health concern, and calcium supplements are still an effective method to relieve the disease. In this study, we investigated the pharmaceutical properties, antiosteoporosis, and adverse effects of a novel calcium supplement named compound calcium carbonate granule (CCCG). The dissolution rate, stability of vitamin D3, and drug permeability of the calcium supplements were explored. And the osteoporosis was constructed in mice with retinoic acid (100mg/kg/d) for 21days, and orally treated with CCCG (0.34, 0.68, and 1.36g/kg/d) for 36days to evaluate the efficacy against osteoporosis and the occurrence of kidney stones. The results showed that CCCG exhibited higher dissolution rate and better vitamin D3 stability than the standard calcium carbonate granule. CCCG also displayed more absorption in Caco-2cell model. On the other hand, CCCG alleviated the deterioration in femur microstructure and oxidative stress in the liver and kidney, and increased the expression of bone metabolic markers. CCCG also exhibited lower risk of nephrolithiasis than the commercial calcium carbonate granule. In summary, from the perspectives of both pharmaceutics and efficacy, we illustrated the profiles of an intriguing calcium supplement, which could possibly be an alternative of commonly used ones. Practical Application. Calcium carbonate is widely used to supplement calcium, primarily because of its high calcium load, low cost, and good efficacy. Now, we provided a new calcium supplement named CCCG, which was prepared by inclusion and complexation techniques. Vitamin D3 in CCCG was made into vitamin D-β-cyclodextrin inclusion complex by inclusion technology, which improved the stability of vitamin D3. And calcium carbonate was converted to a water-soluble calcium citrate complex via complexation techniques to accelerate the release of calcium ions and minimize the risk of kidney stone formation. From the perspective of both pharmaceutics and efficacy, we illustrated the profiles of an intriguing calcium supplement, which could possibly be an alternative for the supplemental and preventive treatment of osteoporosis.